{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T14:51:19Z","timestamp":1786978279298,"version":"build-2736575974"},"reference-count":100,"publisher":"Wiley","issue":"9","license":[{"start":{"date-parts":[[2019,6,17]],"date-time":"2019-06-17T00:00:00Z","timestamp":1560729600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Pediatric Blood &amp; Cancer"],"published-print":{"date-parts":[[2019,9]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Metronomic chemotherapy transitioned from the bench to bedside in the early 2000s and since then has carved a niche for itself in pediatric oncology. It has been used solely or in combination with other modalities such as radiotherapy, maximum tolerated dose chemotherapy, and targeted agents in adjuvant, palliative, as well as maintenance settings. No wonder, the resulting medical literature is extremely heterogeneous. In this review, the authors review and synthesize the published literature in pediatric metronomics giving a glimpse of its history, varied applications, and evolution of this genre of chemotherapy in pediatric cancers. Limitations, future prospects, and grey areas are also highlighted.<\/jats:p>","DOI":"10.1002\/pbc.27811","type":"journal-article","created":{"date-parts":[[2019,6,17]],"date-time":"2019-06-17T14:23:26Z","timestamp":1560781406000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":24,"title":["Metronomic therapy in pediatric oncology: A snapshot"],"prefix":"10.1002","volume":"66","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0483-6254","authenticated-orcid":false,"given":"Raja","family":"Pramanik","sequence":"first","affiliation":[{"name":"Department of Medical Oncology Dr. B. R.A. Institute Rotary Cancer Hospital All India Institute of Medical Sciences  New Delhi India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9367-4407","authenticated-orcid":false,"given":"Sameer","family":"Bakhshi","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology Dr. B. R.A. Institute Rotary Cancer Hospital All India Institute of Medical Sciences  New Delhi India"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2019,6,17]]},"reference":[{"key":"e_1_2_19_2_1","doi-asserted-by":"publisher","DOI":"10.1172\/JCI9872"},{"key":"e_1_2_19_3_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0065-230X(08)60946-X"},{"key":"e_1_2_19_4_1","doi-asserted-by":"publisher","DOI":"10.1172\/JCI8829"},{"issue":"7","key":"e_1_2_19_5_1","first-page":"1878","article-title":"Antiangiogenic scheduling of chemotherapy improves efficacy against experimental drug\u2010resistant cancer","volume":"60","author":"Browder T","year":"2000","journal-title":"Cancer Res"},{"key":"e_1_2_19_6_1","doi-asserted-by":"publisher","DOI":"10.1007\/s12098-012-0759-z"},{"key":"e_1_2_19_7_1","doi-asserted-by":"publisher","DOI":"10.1097\/MPH.0b013e3182024918"},{"key":"e_1_2_19_8_1","doi-asserted-by":"publisher","DOI":"10.1038\/nrclinonc.2016.64"},{"key":"e_1_2_19_9_1","doi-asserted-by":"publisher","DOI":"10.1038\/nrclinonc.2014.89"},{"key":"e_1_2_19_10_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(13)70056-1"},{"key":"e_1_2_19_11_1","doi-asserted-by":"publisher","DOI":"10.4103\/0976-500X.136098"},{"key":"e_1_2_19_12_1","doi-asserted-by":"publisher","DOI":"10.1158\/1535-7163.MCT-09-0583"},{"issue":"15","key":"e_1_2_19_13_1","first-page":"4342","article-title":"Maximum tolerable dose and low\u2010dose metronomic chemotherapy have opposite effects on the mobilization and viability of circulating endothelial progenitor cells","volume":"63","author":"Bertolini F","year":"2003","journal-title":"Cancer Res"},{"key":"e_1_2_19_14_1","doi-asserted-by":"publisher","DOI":"10.1126\/science.1127592"},{"key":"e_1_2_19_15_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2005-11-4570"},{"key":"e_1_2_19_16_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.coi.2008.05.007"},{"key":"e_1_2_19_17_1","doi-asserted-by":"publisher","DOI":"10.3109\/1547691X.2011.642418"},{"key":"e_1_2_19_18_1","doi-asserted-by":"publisher","DOI":"10.1002\/eji.201041235"},{"key":"e_1_2_19_19_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0067904"},{"key":"e_1_2_19_20_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.trecan.2017.03.011"},{"key":"e_1_2_19_21_1","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.28259"},{"key":"e_1_2_19_22_1","doi-asserted-by":"publisher","DOI":"10.2174\/156800909789271503"},{"key":"e_1_2_19_23_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bjc.6605727"},{"key":"e_1_2_19_24_1","doi-asserted-by":"publisher","DOI":"10.1158\/1535-7163.MCT-11-0659"},{"key":"e_1_2_19_25_1","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.0812801106"},{"key":"e_1_2_19_26_1","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-08-3658"},{"key":"e_1_2_19_27_1","doi-asserted-by":"publisher","DOI":"10.1038\/ncponc1317"},{"key":"e_1_2_19_28_1","doi-asserted-by":"publisher","DOI":"10.1097\/01.mph.0000183863.10792.d4"},{"key":"e_1_2_19_29_1","doi-asserted-by":"publisher","DOI":"10.1097\/01.mph.0000243657.64056.c3"},{"key":"e_1_2_19_30_1","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.3984"},{"key":"e_1_2_19_31_1","doi-asserted-by":"publisher","DOI":"10.1002\/pbc.24794"},{"key":"e_1_2_19_32_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-11-0235"},{"key":"e_1_2_19_33_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00432-010-0807-x"},{"key":"e_1_2_19_34_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.leu.2403467"},{"key":"e_1_2_19_35_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1999.17.10.3221"},{"key":"e_1_2_19_36_1","doi-asserted-by":"publisher","DOI":"10.3892\/or.19.5.1219"},{"key":"e_1_2_19_37_1","doi-asserted-by":"publisher","DOI":"10.1097\/01.mph.0000181430.71176.b7"},{"key":"e_1_2_19_38_1","doi-asserted-by":"publisher","DOI":"10.1002\/pbc.10393"},{"key":"e_1_2_19_39_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2012.04.012"},{"key":"e_1_2_19_40_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.canlet.2017.01.040"},{"key":"e_1_2_19_41_1","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.30842"},{"issue":"10","key":"e_1_2_19_42_1","first-page":"4585","article-title":"Radiotherapy and concurrent metronomic chemotherapy in hormone\u2010refractory prostate carcinoma: a Phase I study","volume":"33","author":"Morganti AG","year":"2013","journal-title":"Anticancer Res"},{"key":"e_1_2_19_43_1","doi-asserted-by":"publisher","DOI":"10.4161\/onci.20684"},{"key":"e_1_2_19_44_1","doi-asserted-by":"publisher","DOI":"10.1088\/1478-3975\/9\/6\/065005"},{"key":"e_1_2_19_45_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00280-014-2546-1"},{"key":"e_1_2_19_46_1","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-16-3130"},{"key":"e_1_2_19_47_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.canlet.2017.02.005"},{"key":"e_1_2_19_48_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2015.08.068"},{"key":"e_1_2_19_49_1","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.7929"},{"key":"e_1_2_19_50_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.canlet.2014.07.033"},{"key":"e_1_2_19_51_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-11-0078"},{"key":"e_1_2_19_52_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-15-1853"},{"issue":"7","key":"e_1_2_19_53_1","first-page":"308","article-title":"Combined biodifferentiating and antiangiogenic oral metronomic therapy is feasible and effective in relapsed solid tumors in children: single\u2010center pilot study","volume":"29","author":"Sterba J","year":"2006","journal-title":"Onkologie"},{"key":"e_1_2_19_54_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0149-2918(08)80059-8"},{"key":"e_1_2_19_55_1","doi-asserted-by":"publisher","DOI":"10.1097\/MPH.0b013e3182018ab8"},{"key":"e_1_2_19_56_1","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.358"},{"key":"e_1_2_19_57_1","doi-asserted-by":"publisher","DOI":"10.1159\/000336483"},{"key":"e_1_2_19_58_1","doi-asserted-by":"publisher","DOI":"10.4103\/0019-509X.118741"},{"key":"e_1_2_19_59_1","doi-asserted-by":"publisher","DOI":"10.3747\/co.23.2873"},{"key":"e_1_2_19_60_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2017.0324"},{"key":"e_1_2_19_61_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2018.36.18_suppl.LBA2"},{"key":"e_1_2_19_62_1","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.20544"},{"key":"e_1_2_19_63_1","doi-asserted-by":"publisher","DOI":"10.1002\/pbc.24328"},{"key":"e_1_2_19_64_1","doi-asserted-by":"crossref","first-page":"2015","DOI":"10.1200\/jco.2015.33.15_suppl.tps10079","article-title":"A multicentric study of interval compressed multiagent chemotherapy and metronomic chemotherapy for patients with Ewing sarcoma family of tumors: the Latin American pediatric oncology group trial","volume":"33","author":"Gregianin LJ","year":"2015","journal-title":"J Clin Oncol"},{"key":"e_1_2_19_65_1","doi-asserted-by":"publisher","DOI":"10.3332\/ecancer.2016.672"},{"key":"e_1_2_19_66_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2016.34.15_suppl.e22504"},{"key":"e_1_2_19_67_1","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.30411"},{"key":"e_1_2_19_68_1","doi-asserted-by":"publisher","DOI":"10.1002\/pbc.22821"},{"key":"e_1_2_19_69_1","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2407-11-21"},{"key":"e_1_2_19_70_1","doi-asserted-by":"publisher","DOI":"10.1080\/08880018.2017.1373314"},{"key":"e_1_2_19_71_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2008.20.1764"},{"key":"e_1_2_19_72_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdr051"},{"key":"e_1_2_19_73_1","doi-asserted-by":"publisher","DOI":"10.1002\/pbc.22382"},{"key":"e_1_2_19_74_1","doi-asserted-by":"publisher","DOI":"10.1097\/MPH.0b013e3182331eaf"},{"key":"e_1_2_19_75_1","doi-asserted-by":"publisher","DOI":"10.1002\/pbc.24006"},{"key":"e_1_2_19_76_1","doi-asserted-by":"publisher","DOI":"10.1093\/neuonc\/noy059.094"},{"issue":"2","key":"e_1_2_19_77_1","first-page":"117","article-title":"Concomitant radiotherapy and metronomic temozolomide in pediatric high\u2010risk brain tumors","volume":"49","author":"Sterba J","year":"2002","journal-title":"Neoplasma"},{"key":"e_1_2_19_78_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2006.03.023"},{"key":"e_1_2_19_79_1","doi-asserted-by":"publisher","DOI":"10.1002\/pbc.21381"},{"key":"e_1_2_19_80_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.arcmed.2008.05.008"},{"key":"e_1_2_19_81_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2010.06.115"},{"key":"e_1_2_19_82_1","doi-asserted-by":"publisher","DOI":"10.1002\/pbc.22690"},{"issue":"1","key":"e_1_2_19_83_1","first-page":"134","article-title":"Antiangiogenic combination therapy after local radiotherapy with topotecan radiosensitizer improved quality of life for children with inoperable brainstem gliomas","volume":"100","author":"Kivivuori S\u2010M","year":"2011","journal-title":"Acta Paediatr Oslo Nor 1992"},{"key":"e_1_2_19_84_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00066-013-0513-0"},{"key":"e_1_2_19_85_1","doi-asserted-by":"publisher","DOI":"10.1097\/CAD.0000000000000314"},{"key":"e_1_2_19_86_1","doi-asserted-by":"publisher","DOI":"10.1002\/cam4.699"},{"key":"e_1_2_19_87_1","article-title":"Metronomic four\u2010drug regimen has anti\u2010tumor activity in pediatric low\u2010grade glioma; the results of a Phase II clinical trial","author":"Verschuur A","journal-title":"Front Pharmacol"},{"key":"e_1_2_19_88_1","unstructured":"A clinical trial using metronomic oral low\u2010dose cyclophosphamide alternating with low\u2010dose oral methotrexate with continuous celecoxib and weekly vinblastine in children and adolescents with relapsed or progressing solid tumours. \u2010 full text view \u2010 ClinicalTrials.gov [Internet]. [cited 2019 Jan 30]. Available from:https:\/\/clinicaltrials.gov\/ct2\/show\/NCT01285817"},{"key":"e_1_2_19_89_1","unstructured":"Protracted etoposide during induction therapy for high risk neuroblastoma \u2010 full text view \u2010 ClinicalTrials.gov [Internet]. [cited 2019 Jan 30]. Available from:https:\/\/clinicaltrials.gov\/ct2\/show\/NCT00578864"},{"key":"e_1_2_19_90_1","unstructured":"Metronomic chemotherapy in patients with advanced solid tumor with bone metastasis and advanced pretreated osteosarcoma \u2010 full text view \u2010 ClinicalTrials.gov [Internet]. [cited 2019 Jan 30]. Available from:https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02517918"},{"key":"e_1_2_19_91_1","unstructured":"Allogeneic tumor cell vaccination with oral metronomic cytoxan in patients with high\u2010risk neuroblastoma \u2010 full text view \u2010 ClinicalTrials.gov [Internet]. [cited 2019 Jan 4]. Available from:https:\/\/clinicaltrials.gov\/ct2\/show\/NCT01192555"},{"key":"e_1_2_19_92_1","unstructured":"Metronomic treatment in children and adolescents with recurrent or progressive high risk neuroblastoma \u2010 full text view \u2010 ClinicalTrials.gov [Internet]. [cited 2018 Aug 19]. Available from:https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02641314"},{"key":"e_1_2_19_93_1","unstructured":"Metronomic and targeted anti\u2010angiogenesis therapy for children with recurrent\/progressive medulloblastoma \u2010 full text view \u2010 ClinicalTrials.gov [Internet]. [cited 2019 Jan 4]. Available from:https:\/\/clinicaltrials.gov\/ct2\/show\/NCT01356290"},{"key":"e_1_2_19_94_1","unstructured":"Metro\u2010PD1: a Phase I\/II trial evaluating anti\u2010PD1 (Nivolumab) in combination with metronomic chemotherapy in children and teenagers with refractory\/relapsing solid tumors or Lymphoma \u2010 ICH GCP \u2010 Clinical Trials Registry [Internet]. [cited 2019 Jan 30]. Available from:https:\/\/ichgcp.net\/clinical-trials-registry\/NCT03585465"},{"key":"e_1_2_19_95_1","unstructured":"Metronomics Global Health Initiative [Internet]. [cited 2019 Jan 30]. Available from:http:\/\/metronomics.org\/PROVIN-Phase-I-study-of-a(Accessed January 30 2019)."},{"key":"e_1_2_19_96_1","unstructured":"Phase I dose escalation study of topotecan and pazopanib in children with recurrent\/refractory solid and cns tumours \u2010 full text view \u2010 ClinicalTrials.gov [Internet]. [cited 2019 Jan 4]. Available from:https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02303028"},{"key":"e_1_2_19_97_1","doi-asserted-by":"crossref","unstructured":"BoucheG Andr\u00e9N BanavaliS BertholdF BerrutiA BocciG et\u00a0al.Lessons from the Fourth Metronomic and Anti\u2010angiogenic Therapy Meeting 24\u201325 June 2014 Milan. Ecancermedicalscience.2014Sep 9;8:463.https:\/\/doi.org\/10.3332\/ecancer.2014.463. eCollection 2014.","DOI":"10.3332\/ecancer.2014.463"},{"key":"e_1_2_19_98_1","doi-asserted-by":"publisher","DOI":"10.1593\/tlo.11124"},{"key":"e_1_2_19_99_1","doi-asserted-by":"crossref","unstructured":"PantziarkaP HutchinsonL Andr\u00e9N et\u00a0al.Next generation metronomic chemotherapy\u2010report from the Fifth Biennial International Metronomic and Anti\u2010angiogenic Therapy Meeting 6\u20138 May 2016 Mumbai. ecancermedicalscience [Internet]. 2016 Nov 2 [cited 2019 Jan 5];10. Available from:https:\/\/www.ncbi.nlm.nih.gov\/pmc\/articles\/PMC5130328\/","DOI":"10.3332\/ecancer.2016.689"},{"key":"e_1_2_19_100_1","doi-asserted-by":"publisher","DOI":"10.4103\/0019-509X.117033"},{"key":"e_1_2_19_101_1","doi-asserted-by":"publisher","DOI":"10.1080\/07357900600705599"}],"container-title":["Pediatric Blood &amp; Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fpbc.27811","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/pbc.27811","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/pbc.27811","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/pbc.27811","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,9]],"date-time":"2023-09-09T23:08:05Z","timestamp":1694300885000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/pbc.27811"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,6,17]]},"references-count":100,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2019,9]]}},"alternative-id":["10.1002\/pbc.27811"],"URL":"https:\/\/doi.org\/10.1002\/pbc.27811","archive":["Portico"],"relation":{},"ISSN":["1545-5009","1545-5017"],"issn-type":[{"value":"1545-5009","type":"print"},{"value":"1545-5017","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,6,17]]},"assertion":[{"value":"2018-10-05","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2019-04-24","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2019-06-17","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e27811"}}